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Mycobacteria and Crohn’s disease: The endless storyC. Prantera ∗


















Happy is he who has been able to learn the causes of things”
irgil, Georgics II: 490
Unfortunately Virgil would not have described us,
esearchers of today, as happy, because a definitive expla-
ation of the causes of Crohn’s disease (CD) is not known. In
he opinion of some gastroenterologists, inflammatory bowel
iseases form a mechanistic continuum that comprises, on
ne side Ulcerative colitis (UC) and, on the other side, CD
1]. But CD itself is not a single entity because wide varia-
ion is seen in anatomic location/extent, disease behaviour,
ntestinal and extraintestinal manifestations, and response to
herapy.
Following the most accepted hypothesis, CD happens as a
esult of an inappropriate mucosal immune response to ubiq-
itous environmental factors such as intestinal microflora and
limentary antigens in genetically susceptible individuals [1].
he gene CARD15 or NOD2, associated with CD suscepti-
ility, encodes an intracellular receptor involved in the host’s
nnate immune system and the response to bacteria [2]. This
iscovery strengthens the prominent role of bacteria, among
he other factors, in causing CD [3].
Many other genes are probably involved, and those
ecently discovered interfere with further inflammatory
echanisms. The interactions among different genes and
arious environmental factors account for the difference in
ocation, disease behaviour, symptoms, and response to ther-
py. Given all these facts the hypothesis that CD is caused by
single environmental agent is pretty weak.
At this point one acceptable question that advocates of the
ycobacterial hypothesis should ask is if it is possible that
ome cases classified as CD are mycobacterial disease. Many
ypes of atypical mycobacteria exist: some of them are sapro-
hytic; some others are possibly cause of disease in humans,
articularly in immunosuppressed patients [4]. Among these
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ycobacteria, Mycobacterium avium subspecies paratuber-
ulosis (MAP) is the pathogenic agent of Johne’s disease
JD), a chronic illness in ruminants and other species char-
cterized by granulomatous inflammation of the intestine.
D affects the terminal ileum and caecum, showing lesions
imilar to those of CD.
The MAP story starts in 1984 when a group of American
esearchers first isolated and cultivated, from the intestinal
issue of three patients with CD, one Mycobacterium similar
o the agent of JD. The inoculation of this Mycobacterium in
nfant goat caused a form of CD-like lesions in this animal
5]. So far this experiment has not been repeated.
I try here to analyze from three different points of view
he hypothesis that MAP is the cause of CD: (a) the presence
f MAP in CD patients, (b) the epidemiological connection
nd (c) the response to anti-mycobacterial agents.
a) The identification of MAP in the tissue is problematic.
MAP is a slow growing bacterium; MAP supporters cite
this characteristic as the reason for the many unsuccess-
ful attempts to cultivate it. Some studies have looked
for evidence of the Mycobacterium in the CD tissues,
through culture or DNA analysis, or for the presence of
antibodies against this organism. Attempts at recovery
of atypical Mycobacteria from cultures have met with
variable success [6–8]. In one of the most important
researches on gut mucosal flora no Mycobacteria were
found in washed colonoscopic biopsies of 305 patients
with bowel inflammation [9]. Moreover, since atypical
Mycobacteria are ubiquitous, they can also be present
as innocent bystanders passing through in the mucosal
surface of CD and non-CD individuals. In fact, it is prob-
able that MAP can be transmitted to humans through
the ingestion of contaminated milk or water and, con-
sequently, it could be found in the intestinal lumen. We
know that atypical Mycobacteria can be invasive in AIDS
patients. This property, as in the case of Mycobacterium
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tuberculosis, should be the requisite for being classified
as pathogenic.
Studies of MAP antibodies have given conflicting
results [10–12]. However, given that CD patients also
have presence of antibodies against other bacteria and
various antigens, it is scarcely credible that the presence
of antibodies alone can be proof of MAP infection in CD.
b) From the epidemiological point of view, we know that
CD is a disease frequent in developed countries and in
cities and that there are no supportive data to suggest,
for instance, that agricultural workers are particularly
prone to it [13]. Moreover there is no increased preva-
lence among colleagues and spouses of CD patients, and
there is a concordance of 44% in monozygotic twins in
comparison with 3.9% in dizygotic [14]. All these data
are in contrast with an infectious origin of CD.
c) The last point is devoted to the treatment of CD and its
relationship with MAP hypothesis.
CD is essentially treated with immunosuppressive drugs.
Anti-TNF therapy is highly effective in inducing remission
f active phases and has also shown to heal colonic and ileal
esions [15]. TNF plays a key role in the host response against
uberculosis [16] namely granuloma formation and control
f disease [17]. Seventy cases of tuberculosis, 17 of them
ith disseminated disease, in close temporal association with
he initiation of treatment with anti-TNF agents, have been
eported [18].
These adverse events seem to be a strong argument against
he role of MAP as infectious agent of CD, given that the anti-
NF infusion has never been associated with disseminated
AP in CD.
Moreover, many attempts have been made by using
nti-mycobacterial therapy for obtaining and maintaining
emission of CD. A meta-analysis of eight studies that have
mployed different combination of antimycobacterial drugs
as shown that the treatment does not seem to be effective
ithout a course of corticosteroids to induce remission [19].
nfortunately, the healing of lesions, which is to be expected
n a drug exerting a direct therapeutic effect on the causative
gent of CD, was either not obtained [20] or not reported.
he healing of lesions obtained in 56% of CD, as reported in
he non-controlled study published in this Journal issue is, in
act, rather unusual [21]. Even in the case of frankly positive
rials in future, we will have to exclude generic anti-bacterial
nd immunosuppressive effects of the employed antibiotics.
ut treating MAP infection by anti-bacterial agents could
e unnecessary given a new possible role of MAP and other
ntestinal microorganism in IBD pathogenesis recently delin-
ated.
A paper from England has suggested a link between MAP
nd antibody self-reactivity [22]. An anti-MAP immune
esponse to the microbial peptide could elicit a host autoim-
une response. In this case, the role of MAP could be that
f triggering an autoimmune-mediated dysfunction in CD,
ndependent of its role as pathogen. Other bacteria moreover
[
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an be responsible of eliciting this autoimmune mechanism.
his discovery renews the hypothesis of the role of MAP in
D combining the two prevalent hypotheses of CD patho-
enesis: namely that it is both an autoimmune-mediated and
lso a bacterial disease.
onflict of interest statement
one declared.
eferences
[1] Podolsky DK. Inflammatory bowel disease. N Engl J Med
2002;347:417–29.
[2] Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et
al. Association of NOD2 leucine-rich repeat variants with susceptibility
to Crohn’s disease. Nature 2001;411:599–603.
[3] Prantera C, Scribano ML. Crohn’s disease: the case for bacteria. Ital J
Gastroenterol Hepatol 1999;31:244–6.
[4] Gray JR, Rabeneck L. Atypical Mycobacterial infection of the gastroin-
testinal tract in AIDS patients. Am J Gastroenterol 1989;84:1521–4.
[5] Chiodini RJ, van Kruiningen HJ, Thayer WK, Merkal RS, Coutu JA.
Possible role of mycobacteria in inflammatory bowel disease. I. An
unclassified Mycobacterium species isolated from patients with Crohn’s
disease. Dig Dis Sci 1984;29:1073–9.
[6] Graham DY, Markesich DC, Yoshimura HH. Mycobacteria and
inflammatory bowel disease. Results of culture. Gastroenterology
1987;92:436–42.
[7] Kobayashi K, Blaser MJ, Brown WR. Immunohistochemical examina-
tion for Mycobacteria in intestinal tissues from patients with Crohn’s
disease. Gastroenterology 1989;96:1009–15.
[8] Bull TJ, McMinn EJ, Sidi-Boumedine K, Skull A, Durkin D, Neild
P, et al. Detection and verification of Mycobacterium avium subsp.
paratuberculosis in fresh ileocolonic mucosal biopsy specimens from
individuals with and without Crohn’s disease. J Clin Microbiol
2003;41:2915–23.
[9] Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening–Baucke
V, Ortner M, et al. Mucosal flora in inflammatory bowel disease. Gas-
troenterology 2002;122:44–54.
10] Cho S-N, Brennan PJ, Yoshimura HH, Korelitz BI, Graham DY.
Mycobacterial etiology of Crohn’s disease: serologic study using com-
mon mycobacterial antigens and a species-specific glycolipid antigen
from Mycobacterium paratuberculosis. Gut 1986;27:1353–6.
11] Blaser MJ, Miller RA, Lather J, Singleton JW. Patients with active
Crohn’s disease have elevated serum antibodies to antigens of seven
enteric bacterial pathogens. Gastroenterology 1984;87:888–94.
12] Kobayashi K, Brown WR, Brennan PJ, Blaser MJ. Serum antibodies
to mycobacterial antigens in active Crohn’s disease. Gastroenterology
1988;94:1404–11.
13] Loftus EV. Clinical epidemiology of inflammatory bowel disease: inci-
dence, prevalence, and environmental influences. Gastroenterology
2004;126:1504–17.
14] Tysk C, Lindberg E, Jarnerot G, Floderus-Myrhed B. Ulcerative colitis
and Crohn’s disease in an unselected population of monozygotic and
dizygotic twins. A study of heritability and the influence of smoking.
Gut 1998;29:990–6.
15] Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S,
Colombel JF, et al. Comparison of scheduled and episodic treat-
ment strategies of infliximab in Crohn’s disease. Gastroenterology
2004;126:402–13.
16] Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowen-
stein CJ, et al. Tumor necrosis factor-alpha is required in the protective








54 C. Prantera / Digestive and
17] Senaldi G, Yin S. Corynebacterium parvum- and Mycobacterium bovis
bacillus Calmette-Guerin-induced granuloma formation is inhibited in
TNF receptor I (TNF-RI) knockout mice and by treatment with soluble
TNF-RI. J Immunol 1996;157:5022–6.
18] Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J,
Schwieterman WD, et al. Tuberculosis associated with infliximab,
a tumor necrosis factor alpha–neutralizing agent. N Engl J Med
2001;345:1098–104.
19] Borgaonkar MR, MacIntosh DG, Fardy JM. A meta-analysis of
antimycobacterial therapy for Crohn’s disease. Am J Gastroenterol
2000;95:725–9.
[
isease 39 (2007) 452–454
20] Prantera C, Kohn A, Mangiarotti R, Andreoli A, Luzi C. Antimy-
cobacterial therapy in Crohn’s disease: results of a controlled, double
blind trial with a multiple antibiotic regimen. Am J Gastroenterol
1994;89:513–8.
21] Borody TJ, Bilkey S, Wettstein AR, Leis S, Pang G, Tye S.
Anti-mycobacterial therapy in Crohn’s disease heals mucosa with lon-
gitudinal scars. Dig Liver Dis 2007:39.
22] Polymeros D, Bogdanos DP, Day R, Arioli D, Vergani D, Forbes A.
Does cross-reactivity between Mycobacterium avium paratuberculosis
and human intestinal antigens characterize Crohn’s disease? Gastroen-
terology 2006;131:85–96.
